Thoracic endovascular stent graft repair for ascending aortic diseases.


Journal

Journal of vascular surgery
ISSN: 1097-6809
Titre abrégé: J Vasc Surg
Pays: United States
ID NLM: 8407742

Informations de publication

Date de publication:
11 2019
Historique:
received: 03 09 2018
accepted: 11 01 2019
pubmed: 28 5 2019
medline: 28 5 2020
entrez: 26 5 2019
Statut: ppublish

Résumé

We describe the preliminary results of thoracic endovascular aortic repair (TEVAR) in a group of patients with ascending aortic disease from the Global Registry for Endovascular Aortic Treatment (GREAT). We identified TEVAR performed for diseases truly originating from the ascending aorta. Between July 2011 and May 2015, 5014 patients were enrolled; six (0.12%) were identified and included in the analysis. One further patient was withdrawn from the study due to lack of a signed consent form. Patients having a "zone 0" proximal landing zone reported for their TEVAR without the presence of an ascending aortic disease were not included. Reinterventions of previous open and endovascular repair were also excluded. Three males and three females were treated. Mean age was 69 years ± 10 years (range, 58-83 years). Indication for TEVAR was atherosclerotic aneurysm (n = 4; ruptured, n = 1), complicated type A dissection (n = 1, rupture), and pseudoaneurysm (n = 1). Mean maximum aortic lesion diameter was 60 mm 14 (range, 39-77 mm). Urgent intervention was performed in three (50%) cases. Primary clinical success was 100%. There was no TEVAR-related in-hospital mortality. Open conversion was never required. Complication such as cerebrovascular accidents, valve impairment, or myocardial infarction did not occur. All patients were discharged home alive. No patient was lost at a median follow-up of 26 months (range, 16-72 months). During the follow-up, no patient died and ongoing primary clinical success was maintained in all patients. Reintervention was never required; endoleaks, migrations, fractures, or ruptures were not observed. Preliminary "real-world" experience of ascending TEVAR shows satisfactory outcomes at short-term follow-up. Although concerns remain for "off-label" use of standard devices, TEVAR-related complications were not observed. Longer follow-up data are expected to confirm durability of these results.

Identifiants

pubmed: 31126763
pii: S0741-5214(19)30349-0
doi: 10.1016/j.jvs.2019.01.075
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT01658787']

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1384-1389.e1

Investigateurs

Rodrigo C Bernardes (RC)
Ricardo J Procopio (RJ)
Joel E Schneider (JE)
Ali F AbuRahma (AF)
John A Kaufman (JA)
Benjamin J Pearce (BJ)

Informations de copyright

Copyright © 2019 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Auteurs

Gabriele Piffaretti (G)

Vascular Surgery, Department of Medicine and Surgery, Circolo University Teaching Hospital, University of Insubria School of Medicine, Varese, Italy. Electronic address: gabriele.piffaretti@uninsubria.it.

Viviana Grassi (V)

Vascular Surgery, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, Milan, Italy.

Chiara Lomazzi (C)

Vascular Surgery II, IRCCS Policlinico San Donato, San Donato Milanese, Italy.

William T Brinkman (WT)

Heart Hospital Baylor Plano, Plano, Tex.

Tulio P Navarro (TP)

Hospital das Clínicas da Universidade Federal de Minas Gerais (HC-UFMG), Belo Horizonte, Brazil.

Michael P Jenkins (MP)

St Mary's Hospital, Imperial College Healthcare NHS Trust, London, United Kingdom.

Santi Trimarchi (S)

Thoracic Aortic Research Center, IRCCS Policlinico San Donato, San Donato Milanese, Italy; Department of Biomedical Sciences for Health, University of Milan, Milan, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH